Gait Analysis in Moderate Hemophiliac Patients (AQM-Hemophile)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-29

Study Completion Date

2020-09-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The management of moderate hemophilia is less codified than those of severe patients; because these patients are theoretically less likely to bleed and therefore less likely to develop arthropathies. Nowaways, the question arises as to the appropriateness of this "symptomatic" management for the prevention of the occurrence of hemophilic arthropathies. Indeed, a significant number of moderate hemophiliacs seems to develop severe arthropathies that cause significant disability. However, because of the very small proportion of these patients in the total number of hemophiliacs, data are lacking on the impact of arthropathies on this population. The investigators therefore propose to include moderate hemophiliac patients in the study to carry out an evaluation of gait, using a gait analysis to determine the consequences of arthropathies, even sub-clinical ones, according to the duration of the disease's progression. In an associated way, the analysis of different clinical (joint assessment; quality of life score;...), radiological (radiographic; ultrasound (synovial thickness)), biological (level of associated factors ; other associated marker), in order to provide a complete picture of the articular situation in these patients with moderate haemophilia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical, Functional and Musculoskeletal Differences Between Adult Patients With Hemophilia and Their Healthy Peers

NCT05589662

Hemophilia Arthropathy

UNKNOWN

Postural Assessment, Therapeutic Exercise and Orthotic Devices in the Prevention of Haemophilic Arthropathy

NCT06438406

Haemophilic Arthropathy Orthosis Foot Malalignment

COMPLETED NA

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

NCT01830712

Congenital Bleeding Disorder Haemophilia A With Inhibitors Haemophilia B With Inhibitors

COMPLETED

Anterior vs Posterior Approach for Hip Hemiarthroplasty

NCT04957251

Hip Fractures

ACTIVE_NOT_RECRUITING NA

Patient Blood Management Program in Total Hip or Total Knee Arthroplasty

NCT04137484

Knee Arthropathy Hip Arthropathy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate Hemophilia Arthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Each participant will perform the quantified gait analysis examination and a clinical examination. The experiments will be carried out in a single measurement session, including several steps.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate hemophiliac patients

Each participant will perform a gait analysis and clinical examination

Group Type EXPERIMENTAL

Gait analysis

Intervention Type OTHER

The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gait analysis

The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have moderate Hemophilia A or B.
* Have understood the protocol and signed its consent to participate.
* Patient able to perform a walking test.
* Patient affiliated to a social security system

Exclusion Criteria

* Pregnant women
* Minor
* Majors under guardianship or curatorship
* Refusal to participate;
* Amputee of a lower limb
* Need for technical walking assistance (walking sticks, walker,...).
* Extensive dermatitis of the lower limbs (need for sensor installation for gait analysis);
* Known NYHA (New York Heart Association) grade III or IV heart failure (resting dyspnea);
* Unstable angina or myocardial infarction within three months of inclusion
* Known severe respiratory disease;
* Parkinson's disease, hemiplegia or paraplegia
* Patient unable to understand the objectives or instructions of the study
* Intercurrent pathology likely to modify walking abilities

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No